Aurora Cannabis Rejects Curaleaf's $5 Hostile Bid a Second Time

A sweetened offer meets the same answer

Aurora Cannabis's board has turned down Curaleaf Holdings for a second time. On October 14, 2026, acting on the unanimous recommendation of a special committee of independent directors, the board told shareholders to reject Curaleaf's revised hostile offer for all of Aurora's common shares. That offer was formally amended in a Notice of Variation, Change and Extension filed on October 6.2 Curaleaf now offers US$1.00 in cash plus 0.4013 Curaleaf shares for each Aurora share. Based on Curaleaf's October 2 closing price, that works out to about US$5.00 per share, and the offer stays open until December 4, 2026.3 The first bid valued Aurora at $4 a share, so the revision adds about a dollar.4

The board's message is that shareholders do not need to do anything. Rejecting the bid only means not tendering, and anyone who has already tendered can withdraw through a broker or the proxy firm Kingsdale Advisors.1 "Curaleaf's revised offer still does not reflect the value of the company Aurora shareholders own today," said Executive Chairman and CEO Miguel Martin. He argued that a debt-free Aurora with plenty of cash would be giving up its strength and future upside at a discount.1

My reading is that this is no longer just an argument about price. It has become a fight over process, and the result will depend less on press releases than on whether Aurora can produce a competing bidder before December.

What Aurora objects to

The board laid out five main complaints. First, it says the revised price still significantly undervalues the company, and an updated opinion from its financial adviser backs that up.1 Second, it argues that much of the cash portion would effectively come out of Aurora's own balance sheet. Third, it says most of the increase comes in Curaleaf stock at what it calls an inflated valuation, which leaves Aurora holders fully exposed if Curaleaf's shares fall.1 Fourth, it calls the bid opportunistic, saying it ignores the longer-term earning power of Aurora's global business. Fifth, it says Curaleaf has not backed up its synergy estimates, and that nearly all of any savings would go to Curaleaf's existing shareholders anyway.13

Some coverage adds detail on the structure. Roughly 80% of the revised offer is Curaleaf equity rather than cash. The total cash portion is about US$67 million, which Aurora says it could more than cover from its own reserves.8 The same reporting says the offer has an upper cap but no floor to protect Aurora holders if Curaleaf's stock drops. Under the revised exchange ratio, Aurora shareholders would own only about 9% of the combined company.816 The financial adviser behind the inadequacy opinion is identified as Fort Capital.8

The most important new fact is not in the list of objections. Aurora disclosed that its financial adviser has contacted potential buyers, and several parties have signed confidentiality and standstill agreements and are reviewing company information.510 Aurora says it is weighing a deal with one or more third parties or staying independent. It also says it cannot promise any transaction will result, and it will make a further recommendation once the review is done.25 MJBizDaily read this as Aurora openly inviting rival bids.4

The billion-dollar figures on both sides

Curaleaf's pitch is about scale. It says the combined company would operate in 17 countries, bring in more than $1.5 billion in annual revenue and save at least $40 million a year in costs.10 Aurora disputes the $40 million synergy figure. Even if it holds up, Aurora says, owning about 9% of the combined company would leave its holders with little of the benefit.16

The other large number cuts the opposite way. MJBizDaily notes that Curaleaf carries close to $1 billion in debt. Aurora has no debt apart from lease liabilities.411 That gap explains why the fight keeps coming back to Aurora's balance sheet. Aurora's case is that Curaleaf wants a clean, cash-rich company and is paying for it largely in its own more leveraged stock. Coverage also notes that Aurora has spent years restructuring and writing down assets, and has since rebuilt itself around international medical cannabis, with operations in Canada, Germany, Poland, Australia and New Zealand.16 Aurora also announced on October 8 that it had finished a major expansion of its EU-GMP manufacturing facility in Europe, which it expects to more than double annual flower output.5 The timing supports the board's claim that its growth isn't yet reflected in the share price.

Curaleaf's rebuttal: let us into the data room

Curaleaf responded on October 19 with a statement framed as a series of myths and facts. CEO Boris Jordan said Aurora's board has a fiduciary duty not to "keep the highest bidder out of the room." He accused the board of shutting Curaleaf out while letting unnamed parties do due diligence.1415 Curaleaf calls itself the only bidder with a binding offer. It says its offer conditions are market standard and open to negotiation, but Aurora has not engaged. It also says it can't give fuller synergy detail without the same diligence access others are getting.

On the cash complaint, Curaleaf's answer is that a target's cash becomes part of the combined company in any acquisition. In its view, the only question is whether shareholders get fair value, including for that cash.14 It also rejects the claim that its shares are inflated, pointing out that Aurora's own adviser used Curaleaf's trading price as a reference.16 And it says Aurora's adjusted earnings have fallen sharply over the last two quarters. Aurora blames a change in Canadian medical reimbursement, but Curaleaf says that change affected only one of those quarters.

Curaleaf's sharpest argument is about Aurora's at-the-market share sales. Curaleaf says Aurora sold new shares with no price floor, including at levels well below the offer price over the summer. It asks how a board willing to sell stock at $2.60 can call $5.00, a 92% premium to that price, too low. It also cites ATB Capital Markets, which wrote on October 6 that the revised bid is favorable for Aurora holders and worth more than Aurora's standalone fair value.14 Aurora's case has no ready answer to this point. Its own recent share sales suggest the board was content to issue stock at prices far below what it now says the company is worth.

Where the coverage disagrees

Coverage agrees on the basic terms and the December 4 deadline. It differs sharply on the size of the premium. Curaleaf cites an 86% premium to Aurora's unaffected 30-day volume-weighted average price, and a much larger one if Aurora's cash is excluded.810 Its rebuttal also uses the 92% figure measured against the at-the-market sales.14 TipRanks, by contrast, put the $5 offer at only about a 28% premium to Aurora's Nasdaq price. The gap mostly reflects how much Aurora's stock has risen since the bid became public. That cuts both ways. The market is pricing in a chance of a higher outcome, but the cushion that would protect holders if Curaleaf walked away has shrunk.

Accounts of how the fight began also differ slightly. TipRanks says Curaleaf approached Aurora in June about a friendly merger. Other reporting traces a formal offer circular in mid-August, followed by Aurora's directors' circular in early September.3 Both companies have also gone to the Alberta Securities Commission. Aurora challenged the adequacy of Curaleaf's disclosure, and Curaleaf asked the regulator to stop Aurora from issuing shares while the bid is open.3

What happens before December 4

Canadian law gives target boards wide latitude to reject offers they consider inadequate, as long as the process is informed, independent and run in good faith. Curaleaf's complaint about being kept out of due diligence is aimed at that last test. Its strategy appears to be making the board's process, not just the price, the issue for shareholders.

One reasonable reading is that both sides are partly right. The 'use our own cash' objection is mostly rhetoric, since a buyer always ends up owning the target's cash. The stock-price risk, on the other hand, is real. With most of the offer in Curaleaf stock, no price floor, and an acquirer carrying close to $1 billion in debt, Aurora holders would be taking on risk that the headline $5 figure doesn't show.

But until another bidder appears publicly, shareholders are comparing a firm Curaleaf offer with alternatives that are still hypothetical.16 The confidentiality and standstill agreements show real interest, but no rival offer yet. If a better proposal arrives before December 4, the board's resistance will look justified. If not, shareholders will have to decide whether turning down a substantial premium was worth it, and Curaleaf is likely to keep pressing the diligence issue until they do.